Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Trajectory for the Remicade Biosimilar Market by 2033?
In recent times, the size of the remicade biosimilar market has seen a significant upsurge. It is estimated to show an expansion from $3.2 billion in 2023 to $3.99 billion in 2024, with a compound annual growth rate (CAGR) of 24.4%. Factors such as the launch of remicade (infliximab), advances in biotechnology, expiration of biologics patents, the establishment of regulatory pathways and pressures on healthcare costs have contributed to the historical period growth.
The market size of Remicade biosimilars is expected to witness remarkable growth over the next few years and is predicted to reach $9.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 22.9%. This projected growth during the forecast period is driven by factors such as patent expirations, increasing demand for affordable treatments, development of biosimilar pipelines, reimbursement policies, and market consolidation. Key trends during this period include changes in physician prescription habits, the management of the biosimilar lifecycle, naming conventions for biosimilars, interchangeable biosimilars, and real-world evidence of biosimilar efficacy.
Claim Your Free Sample of the Global Remicade Biosimilar Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp
What Factors Are Leading to Growth in the remicade biosimilar Market?
The remicade biosimilar market’s growth is predicted to be boosted due to an escalation in the occurrence of autoimmune diseases. These diseases, caused by the immune system erroneously damaging the body’s tissues and organs, are effectively treated with remicade biosimilars. They provide a reliable therapy choice to manage inflammation and other symptoms related to these diseases. For example, based on data from the City University of London in October 2021, 7% of the UK population, amounting to 4 million citizens, were diagnosed with autoimmune diseases in the same year. Moreover, upwards of 80 such diseases were discovered with an annually increasing prevalence rate of 3–9%. In correspondence, the Cleveland Clinic reported in July 2021, that 1 out of every 15 individuals in the US had autoimmune diseases, with conditions like Crohn’s disease and ulcerative colitis affecting 1.4 million and lupus affecting 1 million people in 2021. Consequently, the escalating incidence of autoimmune diseases represents a major catalyst for the future expansion of the Remicade biosimilar market.
Which Segments Play a Key Role in Understanding the Remicade Biosimilar Market?
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
What Trends Are Emerging as Game-Changers in the Remicade Biosimilar Market?
Product innovation is becoming a crucial trend within the Remicade biosimilar market. Top firms in the market, such as Amgen Inc., a biotechnology company from the US, are creating groundbreaking products to retain their market standing. For instance, in January 2023, Amgen launched Amjevita, the first biosimilar to Humira, an existing product of AbbVie. The launch was carried out in the United States, with the aim of ensuring it is as effective and safe as the original drug. Amjevita will compete with Humira for market share and it’s intended to treat a range of autoimmune diseases, including rheumatoid arthritis and Crohn’s disease, similar to its counterpart. Humira is one of the priciest drugs globally, bringing in billions of dollars for AbbVie annually. However, Amjevita is anticipated to have a significantly lower cost, which could result in money savings and provide patients with a wider array of treatment options.
Order Now for Fast Delivery of Your Remicade Biosimilar Market Report!
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report
Which Regions Are Setting the Pace for Remicade Biosimilar Market Growth?
Europe was the largest region in the remicade biosimilar market in 2023. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Remicade Biosimilar Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the remicade biosimilar market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Remicade Biosimilar Market Include
1. Remicade Biosimilar Market Executive Summary
2. Remicade Biosimilar Market Segments
3. Remicade Biosimilar Market Size And Template Market Growth Rate
4. Key Remicade Biosimilar Market Trends
5. Major Remicade Biosimilar Market Drivers
……
25. Key Mergers And Acquisitions In The Remicade Biosimilar Market
26. Top Remicade Biosimilar Companies
27. Remicade Biosimilar Market Opportunities And Strategies
28. Remicade Biosimilar Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Insulin biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
Biosimilar Therapeutic Peptides Global Market Report 2024
Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
